The Latest Breaking News from AstraZeneca

AstraZeneca’s Pascal Soriot and Rolls Royce’s Tufan Erginbilgic were among the highest-paid FTSE 100 CEOs, but what they make still trails behind the average pay of S&P 500 CEOs.

Bosses of UK’s biggest companies are now paid 120 times more than average full-time worker in some instances

AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.

A renaissance is stirring in cholesterol treatment, and it could drive Merck, Novartis and other stocks higher, while delivering new choices for millions of patients.

There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.

These five companies may offer higher earnings and return potential with lower risk. Two Leaderboard stocks included.

The annual conference of the American Society of Clinical Oncology is always the biggest event-making cancer conference. And this year, the attention-grabber was AstraZeneca, as its lung and breast cancer drugs significantly slowed the spread of disease in two trials, potentially establishing the medicines as the new standard of care…

The share price recovery has been partly driven by the surge in wholesale energy prices, which is beyond his control

Women with HER2-low incurable secondary disease in Scotland currently have access, while others across the UK do not

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn

Higher-than expected UK inflation figures disappointed the City today, with shares falling as the 2.3% Consumer Price Index reading dashed hopes of a June interest rate cut.